Roche announced today that the results of the 4 year landmark XENDOS study involving 3304 patients demonstrated that the weight loss medication Xenical can prevent or delay the development of type 2 diabetes. Furthermore, the XENDOS study data showed significant and sustained weight loss over the long term1.
Commenting on the results presented at the 9th International Congress on Obesity (ICO) in Sao Paulo, Brazil, Professor Lars Sjstrm the XENDOS principal investigator, said "Against the background of several studies which show lifestyle intervention in the prevention of diabetes to be successful, it is a significant step forward to be able to show that treatment with Xenical in combination with lifestyle modification is more effective than lifestyle intervention alone both in diabetes prevention and weight loss."
"The outstanding XENDOS study results show that Xenical has a key role in combating the diabetes epidemic. Diabetes is a dangerous and expensive complication to obesity - an effective and safe drug that helps to prevent or delay the disease, as well as to maintain weight loss over the long term, is of real value for millions of overweight people at risk of developing diabetes" said William M. Burns, head of the pharmaceutical division at Roche.
XENDOS study results showed that:
Xenical plus lifestyle intervention is significantly better than lifestyle intervention alone in preventing or delaying the development of type 2 diabetes
The risk of developing type 2 diabetes was 37% lower in people treated with Xenical plus lifestyle intervention compared with lifestyle intervention alone
Weight loss, both in the short and the long term, was significantly greater with Xenical plus lifestyle intervention compared with lifestyle intervention alone (-11.4 vs -
'"/>
Contact: Antonia Betts
antonia.betts@sh-international.com
917-295-2335
Shire Health International
26-Aug-2002